Korro Bio, Inc./$KRRO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Korro Bio, Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Ticker

$KRRO
Sector
Primary listing

Employees

92

Korro Bio, Inc. Metrics

BasicAdvanced
$410M
-
-$9.76
-
-

Bulls say / Bears say

Ended Q1 2025 with $139.0 million in cash, cash equivalents and marketable securities, providing runway into 2027 and supporting continued investment in clinical programs. (GlobeNewswire)
Interim readout from the Phase 1/2a REWRITE clinical trial of KRRO-110 for AATD is on track for the second half of 2025 after global expansion of trial sites, demonstrating robust clinical progress and safety. (GlobeNewswire)
Collaboration revenue of $2.55 million in Q1 2025 from the Novo Nordisk partnership validates Korro’s OPERA™ platform and provides non-dilutive funding to support pipeline expansion. (GlobeNewswire)
Net loss widened to $23.4 million in Q1 2025 from $19.6 million a year earlier, reflecting escalating R&D and operational expenses without product revenues. (GlobeNewswire)
Research and development expenses jumped 45% year-over-year to $19.7 million in Q1 2025, intensifying cash burn risk ahead of pivotal clinical readouts. (GlobeNewswire)
Strategic reduction of approximately 20% of the workforce and related $1.2 million restructuring charges may disrupt execution and underline underlying cost pressures. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KRRO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs